Drucker Wealth 3.0 LLC Sells 15,001 Shares of GSK plc (NYSE:GSK)

Drucker Wealth 3.0 LLC decreased its position in shares of GSK plc (NYSE:GSK - Free Report) by 17.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 68,665 shares of the pharmaceutical company's stock after selling 15,001 shares during the period. Drucker Wealth 3.0 LLC's holdings in GSK were worth $2,322,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Dorsey & Whitney Trust CO LLC boosted its position in GSK by 2.5% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company's stock valued at $389,000 after buying an additional 278 shares during the period. Northwest Bank & Trust Co lifted its stake in GSK by 1.3% in the fourth quarter. Northwest Bank & Trust Co now owns 22,405 shares of the pharmaceutical company's stock worth $765,000 after acquiring an additional 289 shares during the period. GC Wealth Management RIA LLC lifted its holdings in GSK by 2.6% in the fourth quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company's stock worth $474,000 after buying an additional 353 shares during the period. Jacobi Capital Management LLC boosted its holdings in shares of GSK by 3.9% during the 4th quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company's stock valued at $352,000 after buying an additional 389 shares in the last quarter. Finally, Gladstone Institutional Advisory LLC lifted its holdings in shares of GSK by 3.4% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 12,221 shares of the pharmaceutical company's stock valued at $413,000 after purchasing an additional 407 shares during the last quarter. Institutional investors own 15.74% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have commented on GSK shares. BNP Paribas initiated coverage on GSK in a research note on Tuesday, April 15th. They set a "neutral" rating and a $35.25 target price on the stock. Morgan Stanley initiated coverage on shares of GSK in a research note on Wednesday, February 12th. They set an "equal weight" rating on the stock. Wall Street Zen upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Hsbc Global Res raised shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $40.58.

GSK Stock Performance

GSK stock traded up $0.68 during midday trading on Thursday, reaching $39.86. 2,109,676 shares of the company's stock traded hands, compared to its average volume of 4,827,114. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.01. The stock has a market cap of $82.23 billion, a P/E ratio of 25.04, a PEG ratio of 1.12 and a beta of 0.51. The stock's 50-day moving average is $37.26 and its 200 day moving average is $36.08.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, topping the consensus estimate of $1.08 by $0.05. GSK had a return on equity of 48.59% and a net margin of 8.13%. The firm had revenue of $10.06 billion during the quarter, compared to analyst estimates of $7.52 billion. During the same period in the prior year, the business posted $0.43 EPS. GSK's revenue was up 2.1% on a year-over-year basis. As a group, analysts anticipate that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be given a dividend of $0.4216 per share. This is a boost from GSK's previous quarterly dividend of $0.39. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.23%. The ex-dividend date is Friday, May 16th. GSK's payout ratio is presently 86.60%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.